Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model.
The objective of this study was to develop an amiodarone hydrochloride (ADHC)-loaded liposome (ADHC-L) formulation and investigate its potential for cardiomyocyte targeting after cardiac radiofrequency ablation (CA) in vivo. The ADHC-L was prepared by thin-film method combined with ultrasonication and extrusion. The preparation process was optimized by Box-Behnken design with encapsulation efficiency as the main evaluation index. The optimum formulation was quantitatively obtained with a diameter of 99.9±0.4 nm, a zeta potential of 35.1±10.9 mV, and an encapsulation efficiency of 99.5%±13.3%. Transmission electron microscopy showed that the liposomes were spherical particles with integrated bilayers and well dispersed with high colloidal stability. Pharmacokinetic studies were investigated in rats after intravenous administration, which revealed that compared with free ADHC treatment, ADHC-L treatment showed a 5.1-fold increase in the area under the plasma drug concentration-time curve over a period of 24 hours (AUC0-24 h) and an 8.5-fold increase in mean residence time, suggesting that ADHC-L could facilitate drug release in a more stable and sustained manner while increasing the circulation time of ADHC, especially in the blood. Biodistribution studies of ADHC-L demonstrated that ADHC concentration in the heart was 4.1 times higher after ADHC-L treatment in CA rat model compared with ADHC-L sham-operated treatment at 20 minutes postinjection. Fluorescence imaging studies further proved that the heart-targeting ability of ADHC-L was mainly due to the CA in rats. These results strongly support that ADHC-L could be exploited as a potential heart-targeting drug delivery system with enhanced bioavailability and reduced side effects for arrhythmia treatment after CA.
Department of Cardiology, Shanghai First People's Hospital of Nanjing Medical University, Shanghai, People's Republic of China.
Ying
Y
Zhuge
Department of Cardiology, Shanghai First People's Hospital of Nanjing Medical University, Shanghai, People's Republic of China.
Zhi-Feng
ZF
Zheng
Department of Pharmaceutics, School of Pharmacy, Shanghai, People's Republic of China.
Mu-Qing
MQ
Xie
Department of Pharmaceutics, School of Pharmacy, Shanghai, People's Republic of China.
Lin
L
Li
Department of Cardiology, Shanghai First People's Hospital of Nanjing Medical University, Shanghai, People's Republic of China.
Fang
F
Wang
Department of Pharmaceutics, School of Pharmacy, Shanghai, People's Republic of China; Shanghai Key Laboratory of Functional Materials Chemistry, East China University of Science and Technology, Shanghai, People's Republic of China.
Feng
F
Gao
D000638:Amiodarone / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001682:Biological Availability; D017115:Catheter Ablation / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods; D065546:Drug Liberation; D008081:Liposomes / Q000008:administration & dosage* / Q000737:chemistry; D008297:Male; D046529:Microscopy, Electron, Transmission; D032383:Myocytes, Cardiac / Q000187:drug effects*; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry; D061848:Optical Imaging; D010316:Particle Size; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D000889:Anti-Arrhythmia Agents; D008081:Liposomes; D000638:Amiodarone
amiodarone hydrochloride; cardiac radiofrequency ablation; cardiomyocyte targeting; liposomes